Skip to main content

Kalaris Therapeutics, Inc.

corporate_fare Company Profile

Kalaris Therapeutics, Inc.

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed KLRS - Latest Insights

KLRS
Apr 13, 2026, 4:19 PM EDT
Filing Type: 424B3
Importance Score:
9
Kalaris Therapeutics Activates $100M At-The-Market Offering, Signaling Substantial Dilution
Sentiment: Negative
View Wiseek Article
KLRS
Apr 13, 2026, 4:18 PM EDT
Filing Type: 424B3
Importance Score:
7
Selling Stockholders Register 5 Million Shares for Resale, Following Recent Private Placement
Sentiment: Negative
View Wiseek Article
KLRS
Apr 10, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Kalaris Therapeutics CFO Resigns; Chief Accounting Officer Assumes Principal Financial Officer Role
Sentiment: Negative
View Wiseek Article
KLRS
Apr 03, 2026, 4:19 PM EDT
Filing Type: S-3
Importance Score:
8
Kalaris Therapeutics Files $350M Universal Shelf & $100M ATM Program, Signaling Significant Future Dilution Potential
Sentiment: Negative
View Wiseek Article
KLRS
Apr 03, 2026, 4:11 PM EDT
Filing Type: S-3
Importance Score:
7
Kalaris Therapeutics Registers 5 Million Shares for Resale by Selling Stockholders
Sentiment: Negative
View Wiseek Article
KLRS
Mar 17, 2026, 4:00 PM EDT
Filing Type: 10-K
Importance Score:
8
Kalaris Therapeutics Reports Full-Year 2025 Results with Strong Cash Position, Extended Runway, and Unremediated Material Weaknesses
Sentiment: Negative
View Wiseek Article
KLRS
Mar 17, 2026, 8:08 AM EDT
Filing Type: 8-K
Importance Score:
8
Kalaris Therapeutics Reports Strong 2025 Financials, $118M Cash, and Extends Runway into Q4 2027
Sentiment: Positive
View Wiseek Article
KLRS
Mar 09, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Kalaris Therapeutics Updates Positive Phase 1a Data for TH103, Extends Cash Runway into Q4 2027
Sentiment: Positive
View Wiseek Article
KLRS
Feb 17, 2026, 8:15 PM EST
Filing Type: 4
Importance Score:
9
Director & 10% Owner Akkaraju Srinivas Reports $5M Stock Purchase
Sentiment: Positive
View Wiseek Article